$VIRX
Viracta Therapeutics, Inc.

2019 Form 10-K Financial Statement

#000156459020009783 Filed on March 10, 2020

View on sec.gov

Income Statement

Concept 2019 2018 Q4 2018
Revenue $2.073M $0.00 $237.0K
YoY Change 774.68% -64.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.950M $2.460M $11.33M
YoY Change -12.18% -10.87% -16.38%
% of Gross Profit
Research & Development $15.41M $3.300M $14.62M
YoY Change 5.45% -10.08% -32.15%
% of Gross Profit
Depreciation & Amortization $0.00 $9.000K
YoY Change 0.0%
% of Gross Profit
Operating Expenses $25.36M $5.760M $25.95M
YoY Change -2.26% -10.42% -26.05%
Operating Profit -$23.29M -$25.71M
YoY Change -9.42% -25.3%
Interest Expense $514.0K -$300.0K $1.154M
YoY Change -55.46% 7.14% -17.34%
% of Operating Profit
Other Income/Expense, Net $472.0K $60.00K $249.0K
YoY Change 89.56% -33.33% -30.25%
Pretax Income -$23.33M -$6.000M -$26.62M
YoY Change -12.34% -9.37% -24.94%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$23.33M -$6.000M -$26.62M
YoY Change -12.34% -9.37% -24.94%
Net Earnings / Revenue -1125.42% -11229.96%
Basic Earnings Per Share
Diluted Earnings Per Share -$9.369M -$5.607M -$26.10M
COMMON SHARES
Basic Shares Outstanding 37.42M
Diluted Shares Outstanding

Balance Sheet

Concept 2019 2018 Q4 2018
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.13M $13.70M $13.70M
YoY Change 112.63% -56.92% -56.85%
Cash & Equivalents $12.76M $13.70M $13.70M
Short-Term Investments $16.36M $0.00 $0.00
Other Short-Term Assets $7.200M $1.500M $1.500M
YoY Change 380.0% 25.0% 27.12%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $36.32M $15.20M $15.20M
YoY Change 138.95% -53.85% -53.84%
LONG-TERM ASSETS
Property, Plant & Equipment $820.0K $11.00K $10.00K
YoY Change 8100.0% -45.0% -50.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $113.0K $110.0K
YoY Change -9.09% -91.82% -92.03%
Total Long-Term Assets $920.0K $124.0K $120.0K
YoY Change 666.67% -91.15% -91.43%
TOTAL ASSETS
Total Short-Term Assets $36.32M $15.20M $15.20M
Total Long-Term Assets $920.0K $124.0K $120.0K
Total Assets $37.24M $15.32M $15.32M
YoY Change 143.08% -55.37% -55.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $790.0K $1.393M $1.390M
YoY Change -43.17% -17.91% -18.24%
Accrued Expenses $3.160M $2.500M $2.530M
YoY Change 24.9% -34.21% -33.07%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.470M $7.400M $7.400M
YoY Change -26.08% 2.78% 2.78%
Total Short-Term Liabilities $9.420M $11.32M $11.32M
YoY Change -16.78% -10.84% -10.73%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $280.0K $8.000K $10.00K
YoY Change 2700.0% -92.86% -90.91%
Total Long-Term Liabilities $280.0K $8.000K $10.00K
YoY Change 2700.0% -92.86% -90.91%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.420M $11.32M $11.32M
Total Long-Term Liabilities $280.0K $8.000K $10.00K
Total Liabilities $9.700M $11.33M $11.33M
YoY Change -14.39% -11.41% -11.42%
SHAREHOLDERS EQUITY
Retained Earnings -$659.5M
YoY Change 4.21%
Common Stock $4.000K
YoY Change 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.54M $3.993M $3.990M
YoY Change
Total Liabilities & Shareholders Equity $37.24M $15.32M $15.32M
YoY Change 143.08% -55.37% -55.37%

Cashflow Statement

Concept 2019 2018 Q4 2018
OPERATING ACTIVITIES
Net Income -$23.33M -$6.000M -$26.62M
YoY Change -12.34% -9.37% -24.94%
Depreciation, Depletion And Amortization $0.00 $9.000K
YoY Change 0.0%
Cash From Operating Activities -$22.19M -$6.500M -$24.40M
YoY Change -9.09% 21.5% -32.48%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$16.29M $0.00 $4.780M
YoY Change -440.79% -100.0% -83.94%
Cash From Investing Activities -$16.29M $0.00 $4.780M
YoY Change -440.69% -100.0% -83.93%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $32.02M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 43.04M 40.00K 6.343M
YoY Change 578.46% -99.84% -74.94%
NET CHANGE
Cash From Operating Activities -22.19M -6.500M -24.40M
Cash From Investing Activities -16.29M 0.000 4.780M
Cash From Financing Activities 43.04M 40.00K 6.343M
Net Change In Cash 4.565M -6.460M -13.28M
YoY Change -134.37% -133.93% -170.19%
FREE CASH FLOW
Cash From Operating Activities -$22.19M -$6.500M -$24.40M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$6.500M -$24.40M
YoY Change 21.5% -32.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019Q2 dei Entity Public Float
EntityPublicFloat
46416000
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity File Number
EntityFileNumber
000-51531
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
94-3295878
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
395 Oyster Point Boulevard
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 400
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2019 dei City Area Code
CityAreaCode
650
CY2019 dei Local Phone Number
LocalPhoneNumber
266-3500
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2019 dei Trading Symbol
TradingSymbol
SNSS
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12761000
CY2019Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
5500000
CY2019Q4 us-gaap Liabilities
Liabilities
9697000
CY2018Q4 us-gaap Assets
Assets
15324000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1393000
CY2018Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
500000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
943000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13696000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1091000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
7396000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
545000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11323000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
15200000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
272000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
113000
CY2018Q4 us-gaap Liabilities
Liabilities
11331000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
11769000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
20998000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
11000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
698562000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
642460000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-682800000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
27543000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
3993000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
37240000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15324000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
20000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
18000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
19714
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
17697
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111393000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37474000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111393000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37474000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2073000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
237000
CY2019 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2018 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
snss:LicenseAndOtherRevenueMember
CY2018 us-gaap Interest Expense
InterestExpense
1154000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
472000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
249000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-23330000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-26615000
CY2019 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
1000
CY2018 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
7000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23329000
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26608000
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
87129000
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
35582000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1109000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
817000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
98000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
791000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
985000
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5465000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1697000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
36322000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3000
CY2019Q4 us-gaap Assets
Assets
37240000
CY2019Q4 snss Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
521000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
192000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
294000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1063000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-602000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-304000
CY2019 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
21000
CY2018 snss Increase Decrease In Accrued Clinical Expense
IncreaseDecreaseInAccruedClinicalExpense
-267000
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
42000
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16364000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1504000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9416000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-659469000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15412000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14615000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9949000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11332000
CY2019 us-gaap Operating Expenses
OperatingExpenses
25361000
CY2018 us-gaap Operating Expenses
OperatingExpenses
25947000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-23288000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-25710000
CY2019 us-gaap Interest Expense
InterestExpense
514000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
21544000
CY2018 snss Adjustments To Additional Paid In Capital Common Stock Preferred Stock And Warrants Issued Net Of Issuance Costs
AdjustmentsToAdditionalPaidInCapitalCommonStockPreferredStockAndWarrantsIssuedNetOfIssuanceCosts
126000
CY2018 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
5991000
CY2018 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
83000
CY2018 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
139000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
164000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2554000
CY2019 snss Issuance Of Common Stock Preferred Stock Net Of Issuance Cost
IssuanceOfCommonStockPreferredStockNetOfIssuanceCost
44604000
CY2019 snss Issuance Of Common Stock Through Controlled Equity Offering Facilities Net Of Issuance Costs
IssuanceOfCommonStockThroughControlledEquityOfferingFacilitiesNetOfIssuanceCosts
464000
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
54000
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
63000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1695000
CY2019 snss Issuance Of Common Stock
IssuanceOfCommonStock
38000000
CY2019 snss Issuance Of Preferred Stock
IssuanceOfPreferredStock
10000000
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3400000
CY2019 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
473000
CY2018 snss Issuance Of Common Stock Through Equity Facilities Gross Proceeds
IssuanceOfCommonStockThroughEquityFacilitiesGrossProceeds
6068000
CY2019 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
9000
CY2018 snss Issuance Of Common Stock Through Equity Facilities Issuance Cost
IssuanceOfCommonStockThroughEquityFacilitiesIssuanceCost
77000
CY2019 us-gaap Profit Loss
ProfitLoss
-23330000
CY2018 us-gaap Profit Loss
ProfitLoss
-26615000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
1749000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
2637000
CY2019 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-70000
CY2018 us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
9000
CY2019 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
116000
CY2018 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-497000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
183000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-622000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22185000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24404000
CY2019 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
20035000
CY2019 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3750000
CY2018 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
4780000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16285000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4780000
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5453000
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
7500000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
12533000
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32022000
CY2019 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
464000
CY2018 snss Proceeds From Issuance Of Common Stock Through Equity Facilities Net
ProceedsFromIssuanceOfCommonStockThroughEquityFacilitiesNet
6040000
CY2019 snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
63000
CY2018 snss Proceeds From Exercise Of Stock Options And Stock Purchase Rights
ProceedsFromExerciseOfStockOptionsAndStockPurchaseRights
303000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43035000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6343000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4565000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13281000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13696000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26977000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
18261000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
695000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
790000
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
21762000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1362000
CY2018 us-gaap Stock Issued1
StockIssued1
448000
CY2018 snss Legal Expenses Accrued As Cost Of Equity Financing Net Of Adjustments
LegalExpensesAccruedAsCostOfEquityFinancingNetOfAdjustments
39000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Significant Estimates and Judgments </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the Company&#8217;s consolidated financial statements and accompanying notes thereto. Actual results could differ materially from these estimates. Estimates, assumptions and judgments made by management include those related to the valuation of marketable securities, equity and related instruments, revenue recognition, stock-based compensation and clinical trial accounting.</p>
CY2018Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
10845000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
10845000
CY2018Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10845000
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10845000
CY2019 us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
0
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
One vote per share
CY2019 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2018 us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0
CY2019 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2018 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0
CY2019 snss Measurement Dates Of Fair Market Value For Employee Stock Purchase Plan Purchases
MeasurementDatesOfFairMarketValueForEmployeeStockPurchasePlanPurchases
At the beginning of a 12-month offering period or at the end of one of the two related six-month purchase periods.
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25088000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10709000
CY2019Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
26656000
CY2019Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
26657000
CY2017Q4 snss Fair Value Of Shares Issuable Under Employee Stock Purchase Plan
FairValueOfSharesIssuableUnderEmployeeStockPurchasePlan
25000
CY2019 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
133322
CY2018 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
104099
CY2019Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
218000
CY2019Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
10293000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10293000
CY2019Q4 snss Marketable Securities Amortized Cost
MarketableSecuritiesAmortizedCost
16363000
CY2019Q4 snss Marketable Securities Gross Unrealized Gains
MarketableSecuritiesGrossUnrealizedGains
1000
CY2019Q4 snss Cash And Cash Equivalents Restricted Cash And Marketable Securities
CashAndCashEquivalentsRestrictedCashAndMarketableSecurities
34600000
CY2019 snss Securities Policy Maturity Limit Period
SecuritiesPolicyMaturityLimitPeriod
P24M
CY2019 snss Securities Policy Dollar Weighted Average Maturity Limit Period
SecuritiesPolicyDollarWeightedAverageMaturityLimitPeriod
P12M
CY2019 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2019Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
0
CY2018Q4 snss Investments Denominated In Euros Owned At Fair Value
InvestmentsDenominatedInEurosOwnedAtFairValue
800000
CY2019Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
690000
CY2018Q4 snss Accrued Outside Service Fees Current
AccruedOutsideServiceFeesCurrent
556000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
220000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
251000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
57000
CY2018Q4 us-gaap Interest Payable Current
InterestPayableCurrent
284000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
120000
CY2019Q4 snss Other Accruals Current
OtherAccrualsCurrent
22000
CY2019Q4 us-gaap Notes Payable
NotesPayable
5500000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.209
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.013
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.010
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1422000
CY2019Q4 snss Share Based Compensation Arrangement Outstanding Securities
ShareBasedCompensationArrangementOutstandingSecurities
25088000
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26510000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1749000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2637000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1600000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2000000
CY2019 us-gaap Dividends Share Based Compensation Cash
DividendsShareBasedCompensationCash
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4160000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1716000
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
720000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5156000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
3151000
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.66
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.00
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
3.27
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.73
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
2.73
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.56
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y2M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M23D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019 us-gaap Deferred Tax Expense From Stock Options Exercised
DeferredTaxExpenseFromStockOptionsExercised
0
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2000000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-23330000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-21132000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-5483000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-23330000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26615000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.071
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.046
CY2018 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.043
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.006
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.159
CY2018 snss Effective Income Tax Rate Reconciliation Provision To Return
EffectiveIncomeTaxRateReconciliationProvisionToReturn
-0.007
CY2019 snss Effective Income Tax Rate Reconciliation Expired No Ls Research And Development Credits And Other Carryforwards
EffectiveIncomeTaxRateReconciliationExpiredNOLsResearchAndDevelopmentCreditsAndOtherCarryforwards
-0.069
CY2018 snss Effective Income Tax Rate Reconciliation Expired No Ls Research And Development Credits And Other Carryforwards
EffectiveIncomeTaxRateReconciliationExpiredNOLsResearchAndDevelopmentCreditsAndOtherCarryforwards
-0.022
CY2019 snss Effective Income Tax Rate Reconciliation Non Qualified Stock Option Cancellations
EffectiveIncomeTaxRateReconciliationNonQualifiedStockOptionCancellations
-0.010
CY2018 snss Effective Income Tax Rate Reconciliation Non Qualified Stock Option Cancellations
EffectiveIncomeTaxRateReconciliationNonQualifiedStockOptionCancellations
-0.029
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
119015000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
114254000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15140000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14885000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
139497000
CY2019Q4 snss Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
152000
CY2019Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
6081000
CY2018Q4 snss Deferred Tax Assets Capitalized Research Cost
DeferredTaxAssetsCapitalizedResearchCost
6134000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3996000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4002000
CY2019Q4 snss Deferred Tax Assets Lease Liabilities
DeferredTaxAssetsLeaseLiabilities
152000
CY2019Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
77000
CY2018Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
79000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
86000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
143000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
144547000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
152000
CY2019Q4 snss Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
144395000
CY2018Q4 snss Deferred Tax Assets Net Before Valuation Allowance
DeferredTaxAssetsNetBeforeValuationAllowance
139497000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
144395000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
139497000
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
23000
CY2019Q4 snss Indemnification Liabilities Incurred
IndemnificationLiabilitiesIncurred
0
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2019 us-gaap Operating Lease Payments Use
OperatingLeasePaymentsUse
1400000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
579000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
294000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
873000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
56000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
817000
CY2019 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000

Files In Submission

Name View Source Status
0001564590-20-009783-index-headers.html Edgar Link pending
0001564590-20-009783-index.html Edgar Link pending
0001564590-20-009783.txt Edgar Link pending
0001564590-20-009783-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g4dj111qdu3k000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snss-10k_20191231.htm Edgar Link pending
snss-20191231.xml Edgar Link completed
snss-20191231.xsd Edgar Link pending
snss-20191231_cal.xml Edgar Link unprocessable
snss-20191231_def.xml Edgar Link unprocessable
snss-20191231_lab.xml Edgar Link unprocessable
snss-20191231_pre.xml Edgar Link unprocessable
snss-ex1029_190.htm Edgar Link pending
snss-ex211_11.htm Edgar Link pending
snss-ex231_10.htm Edgar Link pending
snss-ex311_8.htm Edgar Link pending
snss-ex312_6.htm Edgar Link pending
snss-ex321_7.htm Edgar Link pending